Uterine and ovarian carcinomas have the same major histological subtypes, but whether they originate from the same cell types is a matter of ongoing debate. Uterine and ovarian endometrioid and clear cell carcinoma (ECC) and uterine and ovarian serous carcinoma (SC) may originate in the same location, or share a common lineage of differentiation. Epidemiologically, a common cellular lineage should be reflected in similar risk associations, and we explored the similarity of uterine and ovarian ECC and uterine and ovarian SC. We included 146,316 postmenopausal participants from the Norwegian Women and Cancer Study. Exposure information was taken from self-administered questionnaires, and cancer cases were identified through linkage to the Cancer Registry of Norway. Hazard ratios with 95% confidence intervals for uterine and ovarian carcinoma and their subtypes were calculated using multivariable Cox regression models, and a Wald test was used to check for heterogeneity. During 1.6 million person-years, 1,006 uterine and 601 ovarian carcinomas were identified. Parity, total menstrual lifespan, body mass index and smoking were differentially associated with total uterine and total ovarian carcinoma (p heterogeneity 5 0.041, 0.027, <0.001 and 0.001, respectively). The corresponding associations for uterine and ovarian ECC did not differ significantly (p heterogeneity > 0.05). Smoking was differentially associated with uterine and ovarian SC (p heterogeneity 5 0.021). Our epidemiological analyses do not contradict a common differentiation lineage for uterine and ovarian ECC. Uterine and ovarian SC are less likely to be of a common lineage of differentiation, based on their difference in risk associated with smoking.
Combined, uterine and ovarian carcinoma constitute 9.4% of cancer incidence and 7.8% of cancer mortality in women in developed countries. 1 Uterine and ovarian carcinomas have the same major histological subtypes: endometrioid, serous, clear cell and mucinous. Uterine carcinomas are often endometrioid and ovarian carcinomas are most commonly serous. Endometrioid carcinoma and clear cell carcinoma (ECC) resemble endometrial cell types, and serous carcinoma (SC) resembles cells covering the peritoneum and fallopian tubes. 2 While the uterus and fallopian tubes originate in the M€ ullerian duct, the ovaries are not of M€ ullerian origin, and the resemblance of ovarian carcinomas to these M€ ullerian tissues has been debated. [3] [4] [5] Research now suggests that ovarian ECC arises in endometriosis, whereas ovarian SC originates in the fallopian tube 6 or in the uterus. 7 Endometriosis and other M€ ullerian tissue remnants, known as the secondary M€ ullerian system, can potentially explain the different subtypes occurring in extrauterine locations without a relocation of cells taking place. 8 Additional hypotheses for the origin of ovarian cancers also exist. 3, 9 Shared protective factors of uterine and ovarian carcinoma include having children, using oral contraceptives (OCs) and lower age at menopause. 10, 11 Adiposity increases the risk of uterine carcinoma 12 but is less associated with ovarian carcinoma. [13] [14] [15] Smoking is associated with lower risk of uterine carcinoma 16 but not with overall risk of ovarian carcinoma. [17] [18] [19] Several studies have compared risk estimates for subtypes of uterine or ovarian carcinoma to determine if they have different risk factors. 14, [20] [21] [22] [23] These authors argue that when different subtypes have different risk estimates, they likely have different etiologies.
Here we present hazard ratios for risk factors of uterine and ovarian ECC and SC, and compare the risk factors by location. The shared epidemiology of uterine and ovarian carcinoma has been discussed. 24 To our knowledge, however, no epidemiological studies directly compare the risk factors for uterine and ovarian tumors of the same subtype in one cohort. To further explore the similarities of these cancers, we combined ovarian ECC with uterine carcinomas and recalculated risk estimates.
Material and Methods

Study cohort
The Norwegian Women and Cancer (NOWAC) Study is a population-based prospective cohort. 25 Women born in 1927-1965 were selected at random from the Norwegian Population Registry. They were sent a letter that explained the study and a self-administered questionnaire. Those who returned a completed questionnaire were enrolled in the study. Recruitment took place in two waves: (1) 102,540 participants were enrolled in 1991-1997 (response rate 57%) and (2) 63,232 participants in 2003-2006 (response rate 48.4%). 25 Including delayed additions, the number of participants in this study was 172,478. Follow-up questionnaires were sent at intervals of 5-7 years. The external validity of the NOWAC Study is found to be acceptable. 26 We excluded 6,823 participants with prevalent cancer, 2,749 who were premenopausal during follow-up, 16,480 with self-reported hysterectomy or oophorectomy at baseline or during follow-up, 70 who emigrated or died prior to inclusion and 40 with a negative total menstrual lifespan (TML; defined in the next section) value. The final study cohort included 146,316 postmenopausal women. Of these women, 77,412 (52.9%) had one or more follow-up questionnaires available. Information on age at menarche (and thus TML) was missing for 2,456 women (1.7%), 3,850 (2.6%) had missing information on body mass index (BMI) and 3,128 women (2.1%) had missing information on smoking status.
Study variables
We selected the established risk factors of endometrial and ovarian carcinoma subtypes. 16, 27 All information except age at menopause and body weight was taken from the enrollment questionnaire. Follow-up information related to weight and age at menopause was used if available. Six continuous variables were used. These were (1) age at menarche, (2) age at menopause, (3) parity, (4) cumulative duration of breastfeeding, (5) cumulative duration of OC use and (6) BMI. We used self-reported height and weight 28 to calculate BMI (kg/ m 2 ). In cases where weight at follow-up differed >50 kg from baseline, the lower weight was used. This applied to 18 women. Smoking status at baseline (never/ever) was included as a dichotomous variable.
Total menstrual lifespan was calculated by subtracting the following values from age at menopause: age at menarche, number of years of OC use, 9 months for each child and number of months of cumulative breastfeeding. 11 We studied TML as a continuous variable, and the resulting hazard ratio (HR) was inverted to produce an HR per 1-year decrease in TML. When age at menopause was missing, it was set to 50 years. This is the median age of menopause in the NOWAC Study, and time at risk started at self-reported age at menopause (N 5 59,927), or from age 50 years (N 5 86,389). If different ages at menopause were reported at baseline and follow-up, we used the highest reported age below 53 years. Emigration and death were determined through linkage to Statistics Norway and the Cause of Death Registry.
Pathology
Cancer cases were identified through linkage to the Cancer Registry of Norway. International Classification of Diseases, Revision 7 (ICD-7) codes were used for corpus uteri cancer (ICD-7 code 172) and cancer of the ovary including the fallopian tube (ICD-7 code 175). Tumor morphology and grade were coded according to the International Classification of Diseases for Oncology, Revision 2 and 3 (serous/papillary serous: 8441, 8450, 8460, 8461; endometrioid: 8380, 8382; clear cell: 8310). In our dataset, code 8382 occurred only in the uterus, and codes 8450 and 8461 only on the ovary. Cases with these histologies were, however, not excluded from the analyses. As our women were included in two different waves, and cases were diagnosed over a period of 22 years, we checked for changes in subtype fractions through the years of follow-up.
To increase statistical power, we studied ECC as one group. Nonepithelial tumors (5.8% of uterine and 4.1% of ovarian cancers) were excluded. Nonspecified adenocarcinomas, What's new? Do uterine and ovarian cancers share a common lineage? Depends on the type, new results suggest. To investigate the cancers' cellular origins, these authors compared risk factors between uterine and ovarian endometrioid and clear cell tumors (ECC) and between uterine and ovarian serous carcinoma (SC). If the cancers originate in the same cell types, the authors reasoned, risk factors should pose the same danger for both locales. After evaluating various risk factors, including smoking, parity and obesity, they concluded that uterine and ovarian ECC appear to share a common lineage. However, smoking affects the risk of uterine and ovarian SC differently, suggesting they may arise separately. Significantly different from the cohort (p < 0.002). 2 Includes 186 cases that were not included in the subtype analysis (unspecified adenocarcinoma, squamous carcinoma and infrequent subtypes, including mucinous carcinoma). 3 Includes 755 cases of endometrioid and 13 clear cell carcinomas. 4 Includes 147 cases that were not included in the subtype analysis (unspecified adenocarcinoma, mucinous carcinoma and infrequent subtypes). mucinous carcinoma and other subtypes were included in analyses of total uterine and ovarian carcinoma. Because only 5% of the ovarian carcinomas had the fallopian tube as the location of origin, the hypothesis of a tubal origin of ovarian SC 6 was not investigated.
Statistical analysis
We used Cox proportional hazards regression 29 to calculate HRs with 95% confidence intervals (CIs) for the risk of uterine or ovarian carcinoma and their subtypes. Age was used as follow-up time with a left truncated start of follow-up, given as age at menopause or age at enrollment in the NOWAC Study, whichever was highest. Attained age was the age at event (ovarian or uterine cancer) or the age at censoring, defined as age at emigration, death, other incident cancer except basal cell skin carcinoma or the end of study (31 December 2013) , whichever came first. In the subtype analyses, cases with subtypes other than those under study were censored at time of diagnosis.
We calculated age-adjusted and multivariable estimates with regard to parity, OC use, TML, BMI and smoking. Because TML included OC use and parity, we carried out two multivariable analyses: (1) one that included parity, OC use, BMI and smoking; (2) one that included TML, BMI and smoking. Women with missing information were excluded in the multivariable analyses. There is evidence which suggests that some risk associations are different between endometrioid and clear cell carcinoma. 30 Therefore, we calculated HRs for endometrioid carcinoma in a separate analysis. This was not done for clear cell carcinoma due to the limited number of cases. The proportional hazards assumption was checked using Schoenfeld residuals, and there was no evidence of deviation from proportionality.
Regrouping analysis and heterogeneity tests
The HRs of uterine and ovarian carcinoma and their subtypes were tested for heterogeneity by the Wald test. 31 If no significant differences were found between the HRs for the corresponding subtypes, we grouped ovarian cases of that subtype together with the corresponding uterine subtype. After completing this regrouping, we recalculated HRs for total uterine and ovarian carcinoma, and the heterogeneity test was repeated. All statistical tests were two sided with a 5% significance level. To avoid nondetection of differences between uterine and ovarian ECC and uterine and ovarian SC, no adjustment in multiple testing was adopted for the comparison between uterine and ovarian subtypes.
All analyses were done in RStudio (RStudio, Inc., Boston, MA, USA) running R package version 3.1.3.
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Ethics
The Regional Ethics Committee, REK Nord, approved the NOWAC Study. Written information was provided to the participants. Return of a completed questionnaire was considered consent to participate. Registry linkages were done by 
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Statistics Norway, and participants' identities were concealed from researchers.
Results
Baseline characteristics
Mean age at inclusion was 52.8 years. During 1,629,317 person-years, and a median follow-up of 9.8 years, there were 1,006 cases of uterine carcinoma (mean age at diagnosis 61.7 years) and 601 cases of ovarian carcinoma (mean age at diagnosis 60.0 years). Uterine carcinoma cases differed significantly from the study cohort with regard to all variables studied, while ovarian carcinoma cases only differed with regard to duration of breastfeeding, OC use and TML ( Table  1 ). The percentage of ECC and SC, and of high grade subtypes, fluctuated from year to year and gradually stabilized. Over time, there was a decrease in the proportion of highgrade endometrioid ovarian carcinoma. Additionally, there was an increase in the proportion of ovarian high-grade serous, uterine high-grade endometrioid and uterine highgrade serous carcinoma. More than 50% of the cases occurred after 2006.
Age-adjusted analysis
In the age-adjusted analysis (Table 2) , parity, OC use and TML were negatively associated with both uterine and ovarian carcinoma, whereas BMI and smoking were associated only with uterine carcinoma. Total menstrual lifespan, BMI and smoking were differentially associated with uterine and ovarian carcinoma (p heterogeneity 0.001) ( Fig. 1 and Supporting Information, Table 1 ). In the ECC subtype analysis, parity was the only variable significantly associated with both uterine and ovarian ECC, whereas only the association with BMI was significantly different at the two sites. When ovarian ECC was combined with uterine ECC, the HRs for parity were significantly different, in addition to TML, BMI and smoking. Smoking was differentially associated with the SC subtype ( Fig. 1 and Supporting Information, Table 1 ).
Multivariable analyses
In the multivariable analyses (Table 3) , the direction and magnitude of the HRs were similar to those in the ageadjusted analysis. Both multivariable analyses produced similar results with regard to BMI. The negative association between smoking and uterine SC (Table 3) attained borderline significance after adjustment for TML and BMI (not  shown in table) . Parity, TML, BMI and smoking were differentially associated with total uterine and total ovarian carcinoma (p het 5 0.041, 0.027, <0.001 and 0.001, respectively) ( Fig. 2 and Supporting Information, Table 2 ). In contrast to the ageadjusted comparisons, in the multivariable comparison BMI was no longer differentially associated with uterine and ovarian ECC (p het 5 0.056). Smoking was the only factor that was differentially associated with uterine and ovarian SC (p het 5 0.021) (Fig. 2 and Supporting Information, Table 2 ; results adjusted for TML and BMI are not shown).
In the analysis of endometrioid carcinoma (not combined with clear cell carcinomas), results for uterine endometrioid carcinoma were consistent with those for ECC. For ovarian endometrioid carcinoma, there were minor differences in risk estimates, and the CIs were wider than for ECC. For BMI, the HR for uterine endometrioid carcinoma was 1.10 (95% CI 1.08-1.11) and the HR for ovarian endometrioid 
Regrouping analysis and heterogeneity tests
When ovarian ECC were grouped together with uterine ECC, parity, BMI and smoking remained significantly different ( Fig. 2 and Supporting Information, Table 2 ). For TML, before regrouping the uterine carcinoma HR was 0.93 (95% CI 0.92-0.94) and ovarian carcinoma HR was 0.95 (95% CI 0.93-0.97), with p het 5 0.027. With ECC regrouped, the HRs and 95% CIs for TML remained unchanged while the heterogeneity test attained borderline significance (p het 5 0.051).
Discussion
In this large prospective cohort study, the multivariable HRs of total carcinoma were significantly different with regard to the most important shared risk factors for uterine and ovarian carcinoma, parity and TML, but not OC use. The risk estimates of uterine and ovarian carcinomas were also significantly different with regard to BMI and smoking. We found no significant differences between the HRs of uterine and ovarian ECC. The HRs of uterine and ovarian SC were significantly different with regard to smoking. In the regrouping analysis, the age-adjusted HRs for parity were significantly different, which further differentiated uterine and ovarian carcinoma.
The percentage of ovarian endometrioid carcinoma (6.5%) was lower than that observed in other large studies, while the percentage of ovarian clear cell carcinoma (4.8%) was similar to other observations. 14, 30 Our risk estimates for uterine carcinoma were similar to those from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. 10, 16, 33 Consistent with the low number of uterine clear cell carcinomas relative to endometrioid, the HRs of uterine ECC in our study were more in agreement with those reported for endometrioid carcinoma in a recent meta-analysis. 21 Our results for uterine SC were similar to those from the meta-analysis with regard to smoking and OC use, but not parity and BMI. The meta-analysis includes case-control studies. 21 For ovarian carcinoma and its subtypes, the variables we investigated influenced the risk in the same direction as was observed in studies from EPIC, with some differences in effect size. 14, 34 The associations of ovarian ECC (of which 43% were clear cell) with parity and OC use were intermediate to those of endometrioid carcinoma and clear cell carcinoma reported in the EPIC study. For TML, our estimate was closer to the EPIC estimate for endometrioid ovarian carcinoma. 14 We observed a similar negative association between smoking and uterine SC as in the previously mentioned meta-analysis, 21 and our observations for total uterine carcinomas were similar to those for postmenopausal women in the EPIC study. 16 The nonassociation between smoking and invasive ovarian SC is known from larger studies. 17, 19 Overall, our results suggest that uterine and ovarian ECC are more similar than uterine and ovarian SC. The significant difference in the associations between smoking and SC The table also shows the risk estimates of ovarian and uterine carcinoma with ovarian cases of ECC carcinoma regrouped with uterine carcinoma. contradicts the hypothesis of Massuger et al. 7 They argued that precancerous cells could be transported from the uterus to the ovary. If this was the case, however, we would also expect smoking to be negatively associated with ovarian SC. Molecular evidence against a uterine origin of ovarian SC has already been presented. 35, 36 In our data, cancers involving both fallopian tube and ovary were coded as ovarian, and we also included primary fallopian tube carcinoma in ovarian carcinoma. Thus, our epidemiological findings do not contradict a M€ ullerian lineage of ovarian SC, but the difference in risk factors speak against an intrauterine origin. Our findings do not contradict the hypothesis of a common cellular lineage for uterine and ovarian ECC. 6 Based on the lack of risk differences, we grouped ovarian ECC together with uterine carcinomas and recalculated risk estimates, to further explore the potential similarities of these cancers. The 68 regrouped ovarian ECC comprised 11.3% (68/601) of the total ovarian carcinomas and 6.3% (68/1,074) of the group when combined with uterine carcinomas. For the age-adjusted estimates, the regrouping increased the number of significantly different risk factors between total ovarian and uterine carcinoma. However, with multivariable estimates, the heterogeneity test for TML attained borderline significance. This decrease in significantly different variables may be due to the reduction in number of cases, as the HR estimates for TML were unchanged after the regrouping. The results from both the initial and regrouped outcomes suggest that ovarian ECC has more in common with uterine ECC than with other ovarian carcinomas.
Strengths of our study include its prospective cohort design, national representativeness and near-complete follow-up of cancer diagnoses. 37, 38 One weakness of registry information, however, is that if the cases were reevaluated today, a fraction of the histological subtypes would likely have been diagnosed differently. 39, 40 Although more than half of our cases were diagnosed after 2006, at which time at least ovarian cancer diagnostics had improved, 40 this potential misclassification may have lowered the precision of our risk estimates, thus leading to wider confidence intervals and a failure to detect risk differences.
We used similar statistical methods to calculate risk of uterine and ovarian carcinoma, which ensured that any differences between risk estimates were not a result of differences in the exposure variables. However, we had small numbers of certain subtypes. To increase statistical power, we combined endometrioid and clear cell carcinoma into one category of ECC. Although both are thought to arise in endometriosis, they may arise through different molecular pathways, 41 and risk modifiers may act differently. However, in a recent study of ovarian carcinoma subtype etiology, which investigated many of the same risk factors that we included in this study, only age at menarche and smoking were differentially associated with endometrioid and clear cell carcinoma. 30 We investigated shared risk modifiers for uterine and ovarian carcinoma (parity, OC use and TML), and BMI and smoking, which affect uterine carcinoma risk. These were well-established risk factors 16 ,27 for which we had complete information. We did not have information on endometriosis or tubal ligation. 42, 43 Owing to a small number of cases of tubal carcinoma, we could not test the widely held hypothesis of a tubal origin of serous carcinoma. 
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If most ovarian carcinomas are misclassified tumors of extraovarian origin, the misclassification bias in epidemiological studies of ovarian cancer is potentially very large. 6 Based on multivariable estimates, we found no significant differences between the risk estimates of uterine and ovarian ECC with regard to the most important shared risk factors. Our findings suggest that uterine and ovarian ECC have more in common than uterine and ovarian SC, and that ovarian ECC has more in common with uterine ECC than with other ovarian carcinomas. Regardless of cellular origin, however, the clinical parameters that guide the treatment of intrauterine and extrauterine carcinomas are different. 44 Our results contribute to the ongoing debate surrounding the lineages of differentiation for ovarian and uterine ECC and SC. More results are needed from genetic, molecular, histopathological and epidemiological studies to fully elucidate the origins of these cancers.
